LAVA Therapeutics insider reports multi-day share sales

Rhea-AI Filing Summary

LAVA Therapeutics (LVTX): Insider share sales disclosed on Form 4. A reporting group led by Cooperatieve Gilde Healthcare IV U.A. sold common shares on multiple dates. On 10/13/2025, 47,686 shares were sold at a weighted average price of $1.54, and on 10/14/2025, 227,341 shares were sold at a weighted average price of $1.51. A further 200,000 shares were reported sold on 10/15/2015 at a weighted average price of $1.51.

Following the reported transactions, beneficial ownership was 5,246,492 shares after the first sale, 5,019,151 after the second, and 4,819,151 after the third, all reported as directly held. The filing notes price ranges: $1.53–$1.55, $1.50–$1.55, and $1.49–$1.54, with availability of detailed trade breakdowns upon request. Management entities related to Gilde Healthcare are listed and disclaim beneficial ownership except to the extent of pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cooperatieve Gilde Healthcare IV U.A.

(Last) (First) (Middle)

STADSPLATEAU 36

(Street)

UTRECHT P7 3521 AZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LAVA Therapeutics NV [ LVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/13/2025		S		47,686	D	$1.54(1)	5,246,492	D(2)
Common Shares	10/14/2025		S		227,341	D	$1.51(3)	5,019,151	D(2)
Common Shares	10/15/2015		S		200,000	D	$1.51(4)	4,819,151	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Cooperatieve Gilde Healthcare IV U.A.

(Last) (First) (Middle)

STADSPLATEAU 36

(Street)

UTRECHT P7 3521 AZ

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Gilde Healthcare Holding B.V.

(Last) (First) (Middle)

STADSPLATEAU 36

(Street)

UTRECHT P7 3521 AZ

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This figure is the weighted average sales price of multiple trades ranging from $1.53 to $1.55 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

2. The shares are held directly by Cooperatieve Gilde Healthcare IV U.A. ("Gilde Healthcare"). Gilde Healthcare IV Management BV ("GHCIVM") manages and advises Gilde Healthcare and is owned by Gilde Healthcare Holding BV ("GHH"). Each of GHCIVM and GHH disclaims beneficial ownership of the shares held by Gilde Healthcare, except to the extent of its respective pecuniary interests therein.

3. This figure is the weighted average sales price of multiple trades ranging from $1.50 to $1.55 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

4. This figure is the weighted average sales price of multiple trades ranging from $1.49 to $1.54 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

	Cooperatieve Gilde Healthcare IV U.A., By: /s/ Edwin de Graaf, Managing Director	10/15/2025
	Gilde Healthcare IV Management B.V., By: /s/ Edwin de Graaf, Managing Director	10/15/2025
	Gilde Healthcare Holding B.V., By: /s/ Edwin de Graaf, Managing Director	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Which LVTX insider reported transactions on Form 4?

The reporting persons include Cooperatieve Gilde Healthcare IV U.A., with related managers Gilde Healthcare IV Management B.V. and Gilde Healthcare Holding B.V..

How many LVTX shares were sold on 10/13/2025 and at what price?

On 10/13/2025, 47,686 shares were sold at a weighted average price of $1.54 $1.53–$1.55).

What LVTX transactions were reported on 10/14/2025?

On 10/14/2025, 227,341 shares were sold at a weighted average price of $1.51 $1.50–$1.55).

What was the reported LVTX holding after the transactions?

Beneficial ownership was reported as 5,246,492 shares after the first sale, 5,019,151 after the second, and 4,819,151 after the third.

How are the LVTX shares held according to the filing?

Shares are reported as directly held by Cooperatieve Gilde Healthcare IV U.A.; related entities disclaim beneficial ownership except for pecuniary interests.

What were the weighted average price ranges for the LVTX sales?

The ranges disclosed were $1.53–$1.55, $1.50–$1.55, and $1.49–$1.54 for the respective transactions.